期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

芳香化酶抑制剂治疗乳腺癌研究进展 被引量：12

Advances in aromatase inhibitors for breast cancer treatment
下载PDF
导出
摘要 芳香化酶抑制剂 (AI)是作用于绝经后雄激素向雌激素转化的主要途径芳香化酶的一类药物 ,现主要介绍AI的研究进展及其在乳腺癌治疗中的应用。
作者 闫敏 江泽飞 宋三泰
机构地区 军事医学科学院
出处 《国外医学（肿瘤学分册）》 2003年第2期125-128,共4页 Foreign Medical Sciences (Cancer Section)
关键词 乳腺癌 芳香化酶抑制剂 阿那曲唑 来曲唑 依西美坦 临床应用
分类号 R737.9 [医药卫生—肿瘤] R979.1 [医药卫生—药品]
  • 相关文献

参考文献20

  • 1Howell A, Buzdar A, Robertson J, et al. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer [J]. Breast Cancer Res Treat, 1999,58(2):157-162.
  • 2Buzdar A, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature phase Ⅲ trials[J]. Cancer, 1998,83(6): 1142-1152.
  • 3Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate [J]. J Clin Oncol, 1998, 16(2):453-461.
  • 4Gershanovich M,Chaudri H, Campos D, et al. Letrozole, a new oral aromatase inhibitor:randomized trial comparing 2.5mg daily,0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer [J]. Ann Oncol, 1998,9(6): 639-645.
  • 5Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate following tamoxifen failure in advanced breast cancer: results of a phase Ⅲ randomized double-blind trial [J]. J Clin Oncol, 2000, 18(7): 1399-1411.
  • 6Rose C, Vtoraya O, Pluzanska A, et al. Letrozole (Femara) vs anastrozole (Arimidex) : second-line treatment in postmenopausal women with advanced breast cancer [J]. Proc Am Soc Clin Oncol,2002, 21(1): 34a (Abstract 131).
  • 7Nabholtz J, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postm-enopausal women: results of a North American multicenter randomized trial [J]. J Clin Oncol, 2000,18(22): 3758-3767.
  • 8Bonneterre J,Thurlimann B,Robertson J. Anestrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimldex randomized group efficacy and tolerability study[J]. J Clin Oncol,2000,18(22) :3748-3757.
  • 9Bonneterre J, Buzdar A, Nabholtz J, et al. Anastrozole is superior to tarrtoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma[J]. Cancer, 2001,92(9): 2247-2258.
  • 10Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase Ⅲ study of the international letrozole breast cancer group [ J ]. J Clin Oncol,2001,19(10): 2596-2606.

同被引文献132

引证文献12

二级引证文献32

国外医学（肿瘤学分册）
2003年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部